Avacta Group (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has today announced a trading update for the 17 month period ended 31 December 2019. Revenues for the period, which include the

Avacta Group (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has today announced the appointment of Paul Fry as Non Executive Director with effect from 3 February 2020. Paul has extensive financial

Affimer® reagents are a class of non-antibody binding proteins that have been engineered for a wide range of applications where antibodies and aptamers have limitations. They can be used to detect

Avacta has announced a joint venture with Daewoong Pharmaceuticals to develop mesenchymal stem cell (MSC) therapies incorporating Affimers. The joint venture (JV), will be based in South Korea and entirely

Avacta Group (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has today announced that it has agreed to establish a joint venture in South Korea with Daewoong Pharmaceutical Co. Ltd., a leading Korean

The immune system is a powerful weapon against disease, infections and defective cells. Because cancer cells are the body’s own mutated cells, they are not always recognized by the immune

Affimer Therapeutics: A Novel Human Scaffold for the Generation of Bi-specific Molecules Amrik Basran, PHD Chief Scientific Officer at Avacta Life Sciences will be presenting at the Next Generation Protein

Dr Amrik Basran, Chief Scientific Officer at Avacta, explains the current state of cancer immunotherapy and the challenges of moving into combinations of these innovative treatments. What is the current